Andrew Owen

List of Publications by Year in Descending Order

298 papers	6,663 citations	41 h-index	68 g-index
320 ext. papers	7,937 ext. citations	5.7 avg, IF	5.75 L-index

#	Paper	IF	Citations
298	Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2.. *International Journal of Antimicrobial Agents*, **2022**, 106542	14.3	2
297	Lack of Ronapreve (REGN-CoV; casirivimab and imdevimab) virological efficacy against the SARS-CoV-2 Omicron variant (B.1.1.529) in K18-hACE2 mice. **2022**,		2
296	Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics.. *EBioMedicine*, **2022**, 76, 103856	8.8	3
295	Unlike Chloroquine, Mefloquine Inhibits SARS-CoV-2 Infection in Physiologically Relevant Cells.. *Viruses*, **2022**, 14,	6.2	3
294	Neuroinvasion and Neurotropism by SARS-CoV-2 Variants in the K18-hACE2 Mouse. *Viruses*, **2022**, 14, 1020	6.2	6
293	Impact of long-acting therapies on the global HIV epidemic. *Aids*, **2021**, 35, S137-S143	3.5	7
292	Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development. *Clinical Pharmacology and Therapeutics*, **2021**, 110, 64-68	6.1	11
291	A living WHO guideline on drugs to prevent covid-19. *BMJ, The*, **2021**, 372, n526	5.9	31
290	In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19. *Journal of Antimicrobial Chemotherapy*, **2021**, 76, 1874-1885	5.1	33
289	Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2. *Journal of Antimicrobial Chemotherapy*, **2021**, 76, 2121-2128	5.1	4
288	Shutting the gate before the horse has bolted: is it time for a conversation about SARS-CoV-2 and antiviral drug resistance?. *Journal of Antimicrobial Chemotherapy*, **2021**, 76, 2230-2233	5.1	3
287	Associations between efavirenz concentrations, pharmacogenetics and neurocognitive performance in people living with HIV in Nigeria. *Aids*, **2021**, 35, 1919-1927	3.5	1
286	Drug delivery systems as immunomodulators for therapy of infectious disease: Relevance to COVID-19. *Advanced Drug Delivery Reviews*, **2021**, 178, 113848	18.5	2
285	Evaluation of intranasal nafamostat or camostat for SARS-CoV-2 chemoprophylaxis in Syrian golden hamsters **2021**,		1
284	Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis. *British Journal of Clinical Pharmacology*, **2021**, 87, 2078-2088	3.8	21
283	Long-acting drugs and formulations for the treatment and prevention of HIV infection. *International Journal of Antimicrobial Agents*, **2021**, 57, 106220	14.3	23
282	Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2?. *ACS Infectious Diseases*, **2021**, 7, 1317-1331	5.5	9

281	Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial. *Trials*, **2021**, 22, 3	2.8	0
280	Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2 **2021**,		4
279	Development of a highly sensitive bioanalytical assay for the quantification of favipiravir **2021**,		1
278	In vitro assessment of the potential for dolutegravir to affect hepatic clearance of levonorgestrel. *HIV Medicine*, **2021**, 22, 898-906	2.7	
277	AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter. *Trials*, **2021**, 22, 487	2.8	0
276	Single-dose immunisation with a multimerised SARS-CoV-2 receptor binding domain (RBD) induces an enhanced and protective response in mice. *FEBS Letters*, **2021**, 595, 2323-2340	3.8	10
275	A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19. *Nature Communications*, **2021**, 12, 5469	17.4	23
274	Redispersible nanosuspensions as a plausible oral delivery system for curcumin. *Food Hydrocolloids*, **2021**, 121, 107005	10.6	2
273	Optimisation and validation of a sensitive bioanalytical method for niclosamide **2021**,		1
272	Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection. *Nanoscale*, **2021**, 13, 6410-6416	7.7	2
271	Chasing COVID-19 chemotherapeutics without putting the cart before the horse. *British Journal of Clinical Pharmacology*, **2020**,	3.8	2
270	Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic Modelling. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	4
269	Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics. *Clinical Pharmacology and Therapeutics*, **2020**, 108, 775-790	6.1	75
268	Differential Impact of Nevirapine on Artemether-Lumefantrine Pharmacokinetics in Individuals Stratified by c.516G>T Genotypes. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	3
267	Safety assessment of a new nanoemulsion-based drug-delivery system reveals unexpected drug-free anticoagulant activity. *Nanomedicine*, **2020**, 15, 1361-1373	5.6	
266	Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokinetics. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 1259-1266	5.1	2
265	Pharmacokinetics of HIV therapies in pregnant patients: an update. *Expert Opinion on Drug Metabolism and Toxicology*, **2020**, 16, 449-461	5.5	1
264	-Acetyltransferase 2 Genotypes among Zulu-Speaking South Africans and Isoniazid and -Acetyl-Isoniazid Pharmacokinetics during Antituberculosis Treatment. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	11

263	Designing single trigger/dual-response release and degradation into amine-functional hyperbranched-polydendron nanoprecipitates. *Nanoscale Advances*, **2020**, 2, 5468-5477	5.1	1
262	Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis **2020**,		4
261	CYP2B6*6 Genotype Specific Differences in Artemether-Lumefantrine Disposition in Healthy Volunteers. *Journal of Clinical Pharmacology*, **2020**, 60, 351-360	2.9	1
260	Critical considerations for targeting colorectal liver metastases with nanotechnology. *Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology*, **2020**, 12, e1588	9.2	10
259	Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 640-647	5.1	8
258	Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 628-639	5.1	5
257	Controlled synthesis of calcium carbonate nanoparticles and stimuli-responsive multi-layered nanocapsules for oral drug delivery. *International Journal of Pharmaceutics*, **2020**, 574, 118866	6.5	25
256	Optimization of the synthetic parameters of lipid polymer hybrid nanoparticles dual loaded with darunavir and ritonavir for the treatment of HIV. *International Journal of Pharmaceutics*, **2020**, 588, 119794	6.5	12
255	Influence of selected polymorphisms in disposition genes on lumefantrine pharmacokinetics when coadministered with efavirenz. *Pharmacogenetics and Genomics*, **2020**, 30, 96-106	1.9	1
254	Influence of SLCO1B1 polymorphisms on lopinavir C in Serbian HIV/AIDS patients. *British Journal of Clinical Pharmacology*, **2020**, 86, 1289-1295	3.8	3
253	Safety perspectives on presently considered drugs for the treatment of COVID-19. *British Journal of Pharmacology*, **2020**, 177, 4353-4374	8.6	9
252	In Vitro Determination of the Immunogenic Impact of Nanomaterials on Primary Peripheral Blood Mononuclear Cells. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	2
251	A living WHO guideline on drugs for covid-19. *BMJ, The*, **2020**, 370, m3379	5.9	275
250	Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide versus efavirenz as case studies. *European Journal of Pharmaceutical Sciences*, **2019**, 140, 105068	5.1	10
249	A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	6
248	Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide. *Journal of Antimicrobial Chemotherapy*, **2019**, 74, 1670-1678	5.1	22
247	A Lower Dose of Efavirenz Can Be Coadministered With Rifampicin and Isoniazid in Tuberculosis Patients. *Open Forum Infectious Diseases*, **2019**, 6, ofz035	1	4
246	Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies. *Nature Communications*, **2019**, 10, 1413	17.4	19

245	Improving maraviroc oral bioavailability by formation of solid drug nanoparticles. *European Journal of Pharmaceutics and Biopharmaceutics*, **2019**, 138, 30-36	5.7	16
244	Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus-Infected Individuals. *Clinical Infectious Diseases*, **2019**, 68, 446-452	11.6	18
243	Meta-analysis of the effect of CYP2B6, CYP2A6, UGT2B7 and CAR polymorphisms on efavirenz plasma concentrations. *Journal of Antimicrobial Chemotherapy*, **2019**, 74, 3281-3290	5.1	8
242	Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART. *Journal of Antimicrobial Chemotherapy*, **2019**, 74, 3003-3010	5.1	5
241	Long-Acting Injectable Statins-Is It Time for a Paradigm Shift?. *Molecules*, **2019**, 24,	4.8	3
240	Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK. *European Journal of Pharmaceutics and Biopharmaceutics*, **2019**, 144, 101-109	5.7	18
239	Anhydrous nanoprecipitation for the preparation of nanodispersions of tenofovir disoproxil fumarate in oils as candidate long-acting injectable depot formulations. *Nanoscale Advances*, **2019**, 1, 4301-4307	5.1	4
238	Pharmacogenetics of artemether-lumefantrine influence on nevirapine disposition: Clinically significant drug-drug interaction?. *British Journal of Clinical Pharmacology*, **2019**, 85, 540-550	3.8	2
237	Predicting Drug-Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling. *Journal of Infectious Diseases*, **2019**, 219, 1735-1742	7	26
236	Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers. *Journal of Antimicrobial Chemotherapy*, **2019**, 74, 149-156	5.1	5
235	Towards a Maraviroc long-acting injectable nanoformulation. *European Journal of Pharmaceutics and Biopharmaceutics*, **2019**, 138, 92-98	5.7	17
234	Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum. *Clinical Infectious Diseases*, **2018**, 67, 785-790	11.6	19
233	Telmisartan reverses antiretroviral-induced adipocyte toxicity and insulin resistance in vitro. *Diabetes and Vascular Disease Research*, **2018**, 15, 233-242	3.3	5
232	Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	11
231	Derivation of CYP3A4 and CYP2B6 degradation rate constants in primary human hepatocytes: A siRNA-silencing-based approach. *Drug Metabolism and Pharmacokinetics*, **2018**, 33, 179-187	2.2	8
230	Branched copolymer-stabilised nanoemulsions as new candidate oral drug delivery systems.. *RSC Advances*, **2018**, 8, 12984-12991	3.7	22
229	Long-acting injectable atovaquone nanomedicines for malaria prophylaxis. *Nature Communications*, **2018**, 9, 315	17.4	41
228	Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug-drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 1004-1012	5.1	12

227	Evaluation of universal versus genotype-guided efavirenz dose reduction in pregnant women using population pharmacokinetic modelling. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 165-172	5.1	7
226	Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African mother-infant pairs. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 1013-1019	5.1	18
225	In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents. *Clinical Pharmacokinetics*, **2018**, 57, 255-266	6.2	19
224	The biological challenges and pharmacological opportunities of orally administered nanomedicine delivery. *Expert Review of Gastroenterology and Hepatology*, **2018**, 12, 223-236	4.2	27
223	Assessment of interactions of efavirenz solid drug nanoparticles with human immunological and haematological systems. *Journal of Nanobiotechnology*, **2018**, 16, 22	9.4	15
222	Effect of Pregnancy on the Pharmacokinetic Interaction between Efavirenz and Lumefantrine in HIV-Malaria Coinfection. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	7
221	Prediction and optimization of photo-activated curcumin dosage schedule in human, a promising antimicrobial candidate: A physiologically-based pharmacokinetic (PBPK) modeling. *Proceedings for Annual Meeting of the Japanese Pharmacological Society*, **2018**, WCP2018, PO1-11-30	0	
220	Development of Prodrug Approaches for Long-Acting Nanoformulations of Emtricitabine-Based Regimens. *FASEB Journal*, **2018**, 32, 828.3	0.9	
219	Inhibitory Effects of Commonly Used Excipients on P-Glycoprotein in Vitro. *Molecular Pharmaceutics*, **2018**, 15, 4835-4842	5.6	29
218	The emerging role of physiologically based pharmacokinetic modelling in solid drug nanoparticle translation. *Advanced Drug Delivery Reviews*, **2018**, 131, 116-121	18.5	4
217	Sound understanding of environmental, health and safety, clinical, and market aspects is imperative to clinical translation of nanomedicines. *Nanotoxicology*, **2017**, 11, 147-149	5.3	21
216	Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	10
215	The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine. *Clinical Pharmacology and Therapeutics*, **2017**, 102, 529-536	6.1	20
214	A physiologically based pharmacokinetic model to predict the superparamagnetic iron oxide nanoparticles (SPIONs) accumulation in vivo. *European Journal of Nanomedicine*, **2017**, 9,		4
213	Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	20
212	Integrated pharmacokinetic modelling for accelerated nanomedicine translation. *European Journal of Nanomedicine*, **2017**, 9, 1-3		1
211	Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates. *Pharmacology Research and Perspectives*, **2017**, 5, e00359	3.1	7
210	Lack of interaction of lopinavir solid drug nanoparticles with cells of the immune system. *Nanomedicine*, **2017**, 12, 2043-2054	5.6	5

209	Simulating Intestinal Transporter and Enzyme Activity in a Physiologically Based Pharmacokinetic Model for Tenofovir Disoproxil Fumarate. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	5
208	Intracellular delivery of nano-formulated antituberculosis drugs enhances bactericidal activity. *Journal of Interdisciplinary Nanomedicine*, **2017**, 2, 146-156	4	9
207	In vitro characterisation of solid drug nanoparticle compositions of efavirenz in a brain endothelium cell line. *Journal of Interdisciplinary Nanomedicine*, **2017**, 2, 157-169	4	
206	Efavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico, In Vitro, and In Vivo Investigation. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	15
205	Impact of efavirenz pharmacokinetics and pharmacogenomics on neuropsychological performance in older HIV-infected patients. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, 200-204	5.1	7
204	Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, 190-199	5.1	9
203	**2017**,		2
202	Use of a physiologically based pharmacokinetic model to simulate drug-drug interactions between antineoplastic and antiretroviral drugs. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, 805-811	5.1	11
201	Towards a rational design of solid drug nanoparticles with optimised pharmacological properties. *Journal of Interdisciplinary Nanomedicine*, **2016**, 1, 110-123	4	13
200	Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies. *Nature Communications*, **2016**, 7, 13184	17.4	35
199	Toxicity and inflammatory response in Swiss albino mice after intraperitoneal and oral administration of polyurethane nanoparticles. *Toxicology Letters*, **2016**, 246, 17-27	4.4	14
198	Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy. *Advanced Drug Delivery Reviews*, **2016**, 103, 144-156	18.5	80
197	Opportunities and Challenges in Nanotechnology-enabled Antiretroviral Delivery. *Frontiers in Nanobiomedical Research*, **2016**, 205-239		
196	Stable, polymer-directed and SPION-nucleated magnetic amphiphilic block copolymer nanoprecipitates with readily reversible assembly in magnetic fields. *Nanoscale*, **2016**, 8, 7224-31	7.7	8
195	Emerging nanomedicine applications and manufacturing: progress and challenges. *Nanomedicine*, **2016**, 11, 577-80	5.6	3
194	Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study. *Clinical Pharmacokinetics*, **2016**, 55, 861-873	6.2	38
193	Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake. *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 1031-6	5.1	22
192	Effect of SLCO1B1 Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 617-20	5.9	11

191	Chapter 12:The Challenge of Regulating Nanomedicine: Key Issues. *RSC Drug Discovery Series*, **2016**, 290-314	3.64	7
190	Towards a computational prediction of nanoparticle pharmacokinetics and distribution **2016**, 02,		4
189	Pregnancy affects nevirapine pharmacokinetics: evidence from a CYP2B6 genotype-guided observational study. *Pharmacogenetics and Genomics*, **2016**, 26, 381-9	1.9	8
188	Nanoparticles for Imaging and Imaging Nanoparticles: State of the Art and Current Prospects **2016**, 533-560		
187	Nanoparticle Toxicity: General Overview and Insights Into Immunological Compatibility **2016**, 425-442		1
186	History: Potential, Challenges, and Future Development in Nanopharmaceutical Research and Industry **2016**, 1-16		1
185	Nanopharmacy: Exploratory Methods for Polymeric Materials **2016**, 231-270		0
184	Overview and Presentation of Exploratory Methods for Manufacturing Nanoparticles/Inorganic Materials**2016**, 271-294		
183	Scale-Up and cGMP Manufacturing of Nanodrug Delivery Systems for Clinical Investigations **2016**, 295-330		1
182	Occupational Safety and Health **2016**, 331-354		
181	Micro- and Nano-Tools in Drug Discovery **2016**, 355-378		
180	Drug Targeting in Nanomedicine and Nanopharmacy: A Systems Approach **2016**, 403-424		
179	An Overview of Nanoparticle Biocompatibility for Their Use in Nanomedicine **2016**, 443-468		0
178	Translation to the Clinic: Preclinical and Clinical Pharmacology Studies of Nanoparticles The Translational Challenge **2016**, 469-496		
177	Nanoscale Drugs: A Key to Revolutionary Progress in Pharmacy and Healthcare **2016**, 17-42		1
176	Regulatory Issues in Nanomedicines **2016**, 497-520		1
175	Social Studies of Nanopharmaceutical Research **2016**, 521-532		
174	Nanoparticle-Based Physical Methods for Medical Treatments **2016**, 561-578		

173	Nanodrugs in Medicine and Healthcare: Oral Delivery **2016**, 579-602		
172	Steroidal Nanodrugs Based on Pegylated Nanoliposomes Remote Loaded with Amphipathic Weak Acids Steroid Prodrugs as Anti-Inflammatory Agents **2016**, 603-632		
171	Nanodrugs in Medicine and Healthcare: Pulmonary, Nasal and Ophthalmic Routes, and Vaccination **2016**, 633-648		2
170	A Practical Guide to Translating Nanomedical Products **2016**, 661-696		1
169	The Emergence of Nanopharmacy: From Biology to Nanotechnology and Drug Molecules to Nanodrugs **2016**, 43-62		1
168	Future Outlook of Nanopharmacy: Challenges and Opportunities **2016**, 735-742		
167	Omics-Based Nanopharmacy: Powerful Tools Toward Precision Medicine **2016**, 81-100		
166	Characterization Methods: Physical and Chemical Characterization Techniques **2016**, 135-156		
165	Nanoparticle Characterization Methods: Applications of Synchrotron and Neutron Radiation **2016**, 157-174		
164	Development and Commercialization of Nanocarrier-Based Drug Products **2016**, 697-734		4
163	Understanding and Characterizing Functional Properties of Nanoparticles **2016**, 63-80		
162	Nanostructures in Drug Delivery **2016**, 101-134		2
161	Overview of Techniques and Description of Established Processes **2016**, 175-230		
160	Neurodegenerative Diseases Alzheimer's Disease **2016**, 649-660		
159	Determining the relationship between nanoparticle characteristics and immunotoxicity: key challenges and approaches. *Nanomedicine*, **2016**, 11, 1447-64	5.6	19
158	Validation of Computational Approaches for Antiretroviral Dose Optimization. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 3838-9	5.9	2
157	Development and validation of an LC-MS/MS assay for the quantification of efavirenz in different biological matrices. *Bioanalysis*, **2016**, 8, 2125-34	2.1	1
156	Cytotoxic chemotherapy and the evolution of cellular and viral resistance to antiretroviral therapy in HIV- infected individuals with lymphoma. *HIV Clinical Trials*, **2016**, 17, 197-203		1

155	Pharmacogenetics of nevirapine excretion into breast milk and infants' exposure through breast milk versus postexposure prophylaxis. *Pharmacogenomics*, **2016**, 17, 891-906	2.6	4
154	The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children. *British Journal of Clinical Pharmacology*, **2016**, 82, 185-98	3.8	22
153	Multiple and Co-Nanoprecipitation Studies of Branched Hydrophobic Copolymers and AB Amphiphilic Block Copolymers, Allowing Rapid Formation of Sterically Stabilized Nanoparticles in Aqueous Media. *Macromolecules*, **2015**, 48, 1883-1893	5.5	8
152	Special populations and pharmacogenetic issues in tuberculosis drug development and clinical research. *Journal of Infectious Diseases*, **2015**, 211 Suppl 3, S115-25	7	19
151	Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter. *Frontiers in Pharmacology*, **2015**, 6, 78	5.6	17
150	Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 2816-22	5.1	15
149	Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically defined subgroups of mother-infant pairs: an observational study. *Clinical Infectious Diseases*, **2015**, 61, 453-63	11.6	25
148	No relationship between drug transporter genetic variants and tenofovir plasma concentrations or changes in glomerular filtration rate in HIV-infected adults. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2015**, 68, e56-9	3.1	10
147	Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 555-61	5.1	28
146	Hyperbranched polydendrons: a new nanomaterials platform with tuneable permeation through model gut epithelium. *Chemical Science*, **2015**, 6, 326-334	9.4	28
145	Class-specific relative genetic contribution for key antiretroviral drugs. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 3074-9	5.1	10
144	Synthesis, nanoprecipitation and pH sensitivity of amphiphilic linear-dendritic hybrid polymers and hyperbranched-polydendrons containing tertiary amine functional dendrons. *Soft Matter*, **2015**, 11, 7005-15	3.6	12
143	Misoprostol-induced fever and genetic polymorphisms in drug transporters SLCO1B1 and ABCC4 in women of Latin American and European ancestry. *Pharmacogenomics*, **2015**, 16, 919-28	2.6	10
142	Considerations for clinically-relevant nanomedicine therapies for chronic diseases. *Nanomedicine*, **2015**, 10, 3103-7	5.6	4
141	Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment. *Journal of Controlled Release*, **2015**, 219, 669-680	11.7	31
140	Nanoformulation strategies for the enhanced oral bioavailability of antiretroviral therapeutics. *Therapeutic Delivery*, **2015**, 6, 469-90	3.8	23
139	Augmented Inhibition of CYP3A4 in Human Primary Hepatocytes by Ritonavir Solid Drug Nanoparticles. *Molecular Pharmaceutics*, **2015**, 12, 3556-68	5.6	14
138	Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV. *Clinical Pharmacokinetics*, **2015**, 54, 639-50	6.2	57

137	Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions. *Nanomedicine*, **2015**, 10, 1407-21	5.6	8
136	Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics. *Clinical Pharmacology and Therapeutics*, **2015**, 97, 298-306	6.1	36
135	Towards depersonalized abacavir therapy: chemical modification eliminates HLA-B*57 : 01-restricted CD8+ T-cell activation. *Aids*, **2015**, 29, 2385-95	3.5	14
134	The Application of Nanotechnology to Drug Delivery in Medicine **2015**, 173-223		11
133	Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study. *Clinical Pharmacology and Therapeutics*, **2015**, 98, 406-16	6.1	61
132	Use of in vitro to in vivo extrapolation to predict the optimal strategy for patients switching from efavirenz to maraviroc or nevirapine. *Clinical Pharmacokinetics*, **2015**, 54, 107-16	6.2	2
131	Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trial. *Clinical Infectious Diseases*, **2015**, 60, 1026-32	11.6	21
130	New approaches to antiretroviral drug delivery: challenges and opportunities associated with the use of long-acting injectable agents. *Drugs*, **2014**, 74, 7-13	12.1	30
129	Hyperbranched polydendrons: a new controlled macromolecular architecture with self-assembly in water and organic solvents. *Chemical Science*, **2014**, 5, 1844-1853	9.4	38
128	Research capacity. Enabling the genomic revolution in Africa. *Science*, **2014**, 344, 1346-8	33.3	256
127	Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients. *Journal of Antimicrobial Chemotherapy*, **2014**, 69, 491-9	5.1	48
126	Partial mitigation of gold nanoparticle interactions with human lymphocytes by surface functionalization with a 'mixed matrix'. *Nanomedicine*, **2014**, 9, 2467-79	5.6	13
125	The role of drug transporters in the kidney: lessons from tenofovir. *Frontiers in Pharmacology*, **2014**, 5, 248	5.6	43
124	CYP2B6 516G>T (rs3745274) and smoking status are associated with efavirenz plasma concentration in a Serbian cohort of HIV patients. *Therapeutic Drug Monitoring*, **2014**, 36, 734-8	3.2	10
123	CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults. *Pharmacogenetics and Genomics*, **2014**, 24, 459-63	1.9	21
122	A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication. *Journal of Antimicrobial Chemotherapy*, **2014**, 69, 3275-81	5.1	2
121	Antiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro-in vivo correlation. *Advanced Healthcare Materials*, **2014**, 3, 400-11	10.1	62
120	Is methanol really a bad solvent for poly(n-butyl methacrylate)? Low dispersity and high molecular weight polymers of n-butyl methacrylate synthesised via ATRP in anhydrous methanol. *Polymer Chemistry*, **2014**, 5, 3608-3616	4.9	10

119	Species Similarities and Differences in Pharmacokinetics and Distribution of Antiretroviral Drugs **2014**, 339-360		3
118	Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz. *In Silico Pharmacology*, **2013**, 1, 4	4.3	24
117	Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach. *Clinical Pharmacokinetics*, **2013**, 52, 583-92	6.2	43
116	High-throughput nanoprecipitation of the organic antimicrobial triclosan and enhancement of activity against Escherichia coli. *Journal of Materials Chemistry B*, **2013**, 1, 4455-4465	7.3	13
115	Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 6366-9	5.9	92
114	Transport of gabapentin by LAT1 (SLC7A5). *Biochemical Pharmacology*, **2013**, 85, 1672-83	6	75
113	Reactions of hydrophobic organic nanoparticle mixtures in water: nanoparticle-on-nanoparticle oxidative dye bleaching. *Green Chemistry*, **2013**, 15, 1590	10	3
112	Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients. *Clinical Pharmacokinetics*, **2013**, 52, 543-53	6.2	28
111	Mediation of in vitro cytochrome p450 activity by common pharmaceutical excipients. *Molecular Pharmaceutics*, **2013**, 10, 2739-48	5.6	29
110	Dissecting the relative contribution of OATP1B1-mediated uptake of xenobiotics into human hepatocytes using siRNA. *Xenobiotica*, **2013**, 43, 920-31	2	28
109	Correlates of efavirenz exposure in Chilean patients affected with human immunodeficiency virus reveals a novel association with a polymorphism in the constitutive androstane receptor. *Therapeutic Drug Monitoring*, **2013**, 35, 78-83	3.2	32
108	Interactions between tenofovir and nevirapine in CD4+ T cells and monocyte-derived macrophages restrict their intracellular accumulation. *Journal of Antimicrobial Chemotherapy*, **2013**, 68, 2545-9	5.1	4
107	Predicting intestinal absorption of raltegravir using a population-based ADME simulation. *Journal of Antimicrobial Chemotherapy*, **2013**, 68, 1627-34	5.1	19
106	Rilpivirine inhibits drug transporters ABCB1, SLC22A1, and SLC22A2 in vitro. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 5612-8	5.9	23
105	Nanomedicines for HIV therapy. *Therapeutic Delivery*, **2013**, 4, 153-6	3.8	19
104	RXR gene variants are associated with HIV lipodystrophy. *Pharmacogenetics and Genomics*, **2013**, 23, 438-41	1.9	4
103	Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective. *Future Virology*, **2013**, 8, 871-890	2.4	8
102	Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2013**, 62, 60-6	3.1	11

101	ABCB1 single nucleotide polymorphisms (1236C>T, 2677G>T, and 3435C>T) do not affect transport activity of human P-glycoprotein. *Pharmacogenetics and Genomics*, **2013**, 23, 314-23	1.9	23
100	Sensitive assessment of the virologic outcomes of stopping and restarting non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. *PLoS ONE*, **2013**, 8, e69266	3.7	19
99	A multi-system approach assessing the interaction of anticonvulsants with P-gp. *PLoS ONE*, **2013**, 8, e64854	3.7	24
98	Lamotrigine is a substrate for OCT1 in brain endothelial cells. *Biochemical Pharmacology*, **2012**, 83, 805-14	5.4	60
97	Facile synthesis of complex multi-component organic and organic-magnetic inorganic nanocomposite particles. *Journal of Materials Chemistry*, **2012**, 22, 24744		20
96	Divalent metals and pH alter raltegravir disposition in vitro. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 3020-6	5.9	46
95	Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding. *Pharmacogenomics*, **2012**, 13, 1501-22	2.6	22
94	Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation model. *Clinical Pharmacology and Therapeutics*, **2012**, 92, 494-502	6.1	38
93	Regulation of CYP3A4 and CYP3A5 expression and modulation of "intracrine" metabolism of androgens in prostate cells by liganded vitamin D receptor. *Molecular and Cellular Endocrinology*, **2012**, 364, 54-64	4.4	21
92	Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults. *Antiviral Therapy*, **2012**, 17, 861-8	1.6	25
91	Multicomponent Organic Nanoparticles for Fluorescence Studies in Biological Systems. *Advanced Functional Materials*, **2012**, 22, 2469-2478	15.6	52
90	Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies. *Journal of Antimicrobial Chemotherapy*, **2012**, 67, 675-80	5.1	5
89	Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg. *Journal of Antimicrobial Chemotherapy*, **2012**, 67, 671-4	5.1	22
88	Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting. *Therapeutic Drug Monitoring*, **2012**, 34, 232-5	3.2	29
87	Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 2959-66	5.9	36
86	Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. *Clinical Infectious Diseases*, **2012**, 54, 724-32	11.6	129
85	Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. *Pharmacogenetics and Genomics*, **2012**, 22, 10-9	1.9	35
84	Current Progress in the Pharmacogenetics of Infectious Disease Therapy **2011**, 555-578		2

83	The role of cytokines in the regulation of drug disposition: extended functional pleiotropism?. *Expert Opinion on Drug Metabolism and Toxicology*, **2011**, 7, 341-52	5.5	11
82	The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein. *Biochemical and Biophysical Research Communications*, **2011**, 408, 344-9	3.4	15
81	IFN-□874A>T genotype is associated with higher CCR5 expression in peripheral blood mononuclear cells from HIV+ patients. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2011**, 58, 442-5	3.1	3
80	Adipogenic gene variants in patients with HIV-associated lipodystrophy. *Pharmacogenetics and Genomics*, **2011**, 21, 76-83	1.9	6
79	Sequence and gene expression of chloroquine resistance transporter (pfcrt) in the association of in vitro drugs resistance of Plasmodium falciparum. *Malaria Journal*, **2011**, 10, 42	3.6	20
78	Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. *Molecular Cancer*, **2011**, 10, 37	42.1	166
77	Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. *Journal of Antimicrobial Chemotherapy*, **2011**, 66, 2092-8	5.1	87
76	Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. *Journal of Antimicrobial Chemotherapy*, **2011**, 66, 1332-9	5.1	42
75	Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. *Journal of Infectious Diseases*, **2011**, 204, 145-53	7	92
74	The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 4122-7	5.9	101
73	Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 879-87	5.9	51
72	Prevalence of potential drug-drug interactions involving antiretroviral drugs in a large Kenyan cohort. *PLoS ONE*, **2011**, 6, e16800	3.7	33
71	The accumulation and metabolism of zidovudine in 3T3-F442A pre-adipocytes. *British Journal of Pharmacology*, **2010**, 159, 484-93	8.6	7
70	Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism. *Pharmacogenetics and Genomics*, **2010**, 20, 759-65	1.9	38
69	Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort. *Journal of Antimicrobial Chemotherapy*, **2010**, 65, 1889-93	5.1	38
68	Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 5242-50	5.9	63
67	Effect of prototypical inducers on ligand activated nuclear receptor regulated drug disposition genes in rodent hepatic and intestinal cells. *Acta Pharmacologica Sinica*, **2010**, 31, 51-65	8	11
66	HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. *Pharmacogenetics and Genomics*, **2010**, 20, 112-20	1.9	142

65	Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes. *Journal of Antimicrobial Chemotherapy*, **2009**, 64, 1002-7	5.1	36
64	Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. *Clinical Infectious Diseases*, **2009**, 48, e108-16	11.6	200
63	Plasmodium falciparum and dihydrofolate reductase I164L mutations in Africa. *Antimicrobial Agents and Chemotherapy*, **2009**, 53, 1722; author reply 1722-3	5.9	1
62	Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC. *British Journal of Clinical Pharmacology*, **2009**, 68, 375-80	3.8	12
61	The relationships of ABCB1 3435C>T and CYP2B6 516G>T with high-density lipoprotein cholesterol in HIV-infected patients receiving Efavirenz. *Clinical Pharmacology and Therapeutics*, **2009**, 86, 204-11	6.1	12
60	The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC. *British Journal of Pharmacology*, **2009**, 156, 497-508	8.6	64
59	Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. *HIV Medicine*, **2009**, 10, 310-7	2.7	66
58	Nanomedicine: Not a case of One size fits all *Nano Today*, **2009**, 4, 382-384	17.9	14
57	The impact of pharmacogenetics on HIV therapy. *International Journal of STD and AIDS*, **2009**, 20, 145-51	1.4	21
56	Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir. *British Journal of Pharmacology*, **2008**, 155, 875-83	8.6	38
55	Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells. *British Journal of Pharmacology*, **2008**, 153, 805-19	8.6	87
54	Detection of ABCC2, CYP2B6 and CYP3A4 in human peripheral blood mononuclear cells using flow cytometry. *Journal of Immunological Methods*, **2008**, 339, 270-4	2.5	9
53	Plasmodium falciparum strains harboring dihydrofolate reductase with the I164L mutation are absent in Malawi and Zambia even under antifolate drug pressure. *Antimicrobial Agents and Chemotherapy*, **2008**, 52, 3883-8	5.9	10
52	Drug-regulated expression of Plasmodium falciparum P-glycoprotein homologue 1: a putative role for nuclear receptors. *Antimicrobial Agents and Chemotherapy*, **2008**, 52, 1438-45	5.9	5
51	Acridinediones: selective and potent inhibitors of the malaria parasite mitochondrial bc1 complex. *Molecular Pharmacology*, **2008**, 73, 1347-55	4.3	73
50	Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. *Journal of Antimicrobial Chemotherapy*, **2008**, 61, 914-8	5.1	155
49	Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir. *Clinical Infectious Diseases*, **2008**, 47, 1222-5	11.6	73
48	Detection of low-frequency K103N mutants after unstructured discontinuation of efavirenz in the presence of the CYP2B6 516 TT polymorphism. *Journal of Antimicrobial Chemotherapy*, **2008**, 62, 1188-90	5.1	2

47	Pharmacogenetics of antiretroviral agents. *Current Opinion in HIV and AIDS*, **2008**, 3, 288-95	4.2	9
46	Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein. *Tuberculosis*, **2007**, 87, 248-55	2.6	94
45	Detection and quantification of minority HIV isolates harbouring the D30N mutation by real-time PCR amplification. *Journal of Antimicrobial Chemotherapy*, **2007**, 60, 881-4	5.1	7
44	Factors impacting the expression of membrane-bound proteins in lymphocytes from HIV-positive subjects. *Journal of Antimicrobial Chemotherapy*, **2007**, 60, 685-9	5.1	18
43	Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. *Journal of Antimicrobial Chemotherapy*, **2007**, 60, 987-93	5.1	92
42	Tacrine-induced liver damage: an analysis of 19 candidate genes. *Pharmacogenetics and Genomics*, **2007**, 17, 1091-100	1.9	31
41	Detection and biochemical characterisation of a novel polymorphism in the human GSTP1 gene. *Biochimica Et Biophysica Acta - General Subjects*, **2007**, 1770, 1240-7	4	7
40	The impact of host pharmacogenetics on antiretroviral drug disposition. *Current Infectious Disease Reports*, **2006**, 8, 401-8	3.9	6
39	Development of a transactivator in hepatoma cells that allows expression of phase I, phase II, and chemical defense genes. *American Journal of Physiology - Cell Physiology*, **2006**, 290, C104-15	5.4	25
38	Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug. *Annals of the Rheumatic Diseases*, **2006**, 65, 1390-3	2.4	19
37	Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. *Clinical Pharmacokinetics*, **2006**, 45, 213-4; author reply 214-5	6.2	1
36	Pharmacogenetics of HIV therapy. *Pharmacogenetics and Genomics*, **2006**, 16, 693-703	1.9	34
35	Exon sequencing and high resolution haplotype analysis of ABC transporter genes implicated in drug resistance. *Pharmacogenetics and Genomics*, **2006**, 16, 439-50	1.9	58
34	Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: the role of nuclear hormone response elements. *British Journal of Clinical Pharmacology*, **2006**, 62, 237-42	3.8	38
33	Mitochondria are sensors for HIV drugs. *Trends in Pharmacological Sciences*, **2005**, 26, 258-64	13.2	26
32	Host determinants of antiretroviral drug activity. *Current Opinion in Infectious Diseases*, **2005**, 18, 543-9	5.4	13
31	Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. *Aids*, **2005**, 19, 2097-102	3.5	76
30	The implications of P-glycoprotein in HIV: friend or foe?. *Fundamental and Clinical Pharmacology*, **2005**, 19, 283-96	3.1	40

29	Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver. *British Journal of Clinical Pharmacology*, **2005**, 59, 365-70	3.8	64
28	In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine. *Journal of Pharmacology and Experimental Therapeutics*, **2005**, 314, 1202-9	4.7	23
27	Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4. *Journal of Virology*, **2004**, 78, 12022-9	6.6	41
26	Whole-blood cultures from renal-transplant patients stimulated ex vivo show that the effects of cyclosporine on lymphocyte proliferation are related to P-glycoprotein expression. *Transplantation*, **2004**, 77, 557-61	1.8	17
25	Expression of pregnane-X-receptor transcript in peripheral blood mononuclear cells and correlation with MDR1 mRNA. *Antiviral Therapy*, **2004**, 9, 819-21	1.6	23
24	Intracellular pharmacokinetics of antiretroviral agents. *Journal of HIV Therapy*, **2004**, 9, 97-101		17
23	Expression of Pregnane-X-Receptor Transcript in Peripheral Blood Mononuclear Cells and Correlation with Mdr1 Mrna. *Antiviral Therapy*, **2004**, 9, 819-821	1.6	45
22	The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2003**, 33, 551-6	3.1	85
21	Expression of P-glycoprotein, multidrug-resistance proteins 1 and 2 in CEM, CEMVBL, CEME1000, MDCKIIMRP1 and MDCKIIMRP2 cell lines. *Aids*, **2003**, 17, 2276-2278	3.5	7
20	A simplified approach to determining P-glycoprotein expression in peripheral blood mononuclear cell subsets. *Journal of Immunological Methods*, **2003**, 274, 129-37	2.5	25
19	The mechanisms that control intracellular penetration of the HIV protease inhibitors. *Journal of Antimicrobial Chemotherapy*, **2003**, 51, 493-6	5.1	33
18	Differential expression of human immunodeficiency virus coreceptors, by CEM, CEMVBL, and CEM E1000 cells. *Journal of Infectious Diseases*, **2003**, 187, 874-5; author reply 875-6	7	6
17	Expression of P-glycoprotein, multidrug-resistance proteins 1 and 2 in CEM, CEM(VBL), CEM(E1000), MDCKII(MRP1) and MDCKII(MRP2) cell lines. *Aids*, **2003**, 17, 2276-8	3.5	2
16	LC determination of carbamazepine in murine brain. *Journal of Pharmaceutical and Biomedical Analysis*, **2001**, 26, 573-7	3.5	14
15	Carbamazepine is not a substrate for P-glycoprotein. *British Journal of Clinical Pharmacology*, **2001**, 51, 345-9	3.8	111
14	SARS-CoV-2 Omicron-B.1.1.529 Variant leads to less severe disease than Pango B and Delta variants strains in a mouse model of severe COVID-19		31
13	Integrase as a Novel Target for the Inhibition of Human Immunodeficiency Virus Type 1 Infection: Current Status and Future Perspectives71-96		1
12	Handbook of Immunological Properties of Engineered Nanomaterials		3

11	Physiologically-based pharmacokinetic modelling of infant exposure to efavirenz through breastfeeding. *AAS Open Research*,1, 16	1.8	7
10	Viral and antiretroviral dynamics in HIV mother-to-child transmission fluids (VADICT) Protocol and data analysis plan for a cohort study. *Wellcome Open Research*,4, 34	4.8	2
9	Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate plasma and target site concentrations derived from their established human pharmacokinetics		11
8	The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2		13
7	Sequential infection with influenza A virus followed by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leads to more severe disease and encephalitis in a mouse model of COVID-19		7
6	Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro antiviral activity against SARS-CoV-2		5
5	Viral neuroinvasion and neurotropism without neuronal damage in the hACE2 mouse model of COVID-19		3
4	Single-dose immunisation with a multimerised SARS-CoV-2 receptor binding domain (RBD) induces an enhanced and protective response in mice		2
3	Unlike Chloroquine, mefloquine inhibits SARS-CoV-2 infection in physiologically relevant cells and does not induce viral variants		1
2	Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry. *Wellcome Open Research*,6, 246	4.8	
1	Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry. *Wellcome Open Research*,6, 246	4.8	